2019nCoV, 2019-nCoV, Coronavirus, COVID-19, SARS-CoV-2
Conditions
Keywords
coronavirus, health education, personalized health education, randomized controlled trial, intensive care, multi organ failure, prevention
Brief summary
The additional effect of personalized health education compared to general education following the internationally accepted principles will be evaluated in the prevention of the serious course of the novel coronavirus infection. It is hypothesised that personalized health education provides a greater degree of lifestyle change, thus the risk of a serious course of infection decreases.
Detailed description
PROACTIVE-19 is a pragmatic, randomized controlled clinical trial with adaptive sample size re-estimation design. Volunteers will be randomized into two groups: (A) generalized health education; (B) personalized health education. Participants will go through phone questioning and recommendation in 5 fields: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits, (5) alcohol consumption. Both groups A and B will receive the same line of questioning to assess habits concerning these topics. In Group A: questioning will be done in sequence followed by a shared minimal intervention aimed towards improvement of these factors but without any personalized recommendation. In Group B: each assessment will be followed by specific and personalized recommendations. Assessment will be done weekly during the first month, every second week in the second month, then monthly. Considering one interim analysis for efficacy the estimated sample size is 3788 (rounded up to 3800) subject per study arm. The planned duration of the follow up is a minimum of one year.
Interventions
Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive detailed individualized education regarding lifestyle changes based on their current habits.
Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive general health education aiming towards improvement of these factors with general recommendations following the WHO principles.
Sponsors
Study design
Masking description
Subjects will be blinded to knowledge of the details of differences between the interventions. Everyone else (outcome assessors, caregivers and data analysts) will be blinded regarding the allocation.
Intervention model description
This is a randomized controlled, adaptive, two-arm, parallel trial. The target patient population consists of adults age above 60 years without confirmed COVID-19 infection or current hospitalization. The sample size calculation suggests that 7576 subjects (3788/ each arm) are required. The allocation ratio is 1:1. Eligible participants in the generalized health education intervention arm will receive healthy lifestyle advice according to World Health Organization (WHO) principles. On the personalized education arm, participants will receive detailed informative intervention regarding lifestyle changes based on their current habits.
Eligibility
Inclusion criteria
The inclusion criteria are: 1. age over 60 years; 2. informed consent to participate. The
Exclusion criteria
are: 1. confirmed COVID-19 infection (active or recovered); 2. hospitalization at screening for eligibility; 3. someone was already enrolled in the study from the same community/household (to avoid potential crosstalk between the study arms).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary composite rate of intensive care unit (ICU) admission, 48 hours of hospital admission, death in COVID-19 positive cases | 12 months | The primary endpoint will be the composite of the rate of the followings in COVID-19 positive cases (verified by an accredited laboratory): the number of pariticipants with ICU (intensive care unit) admission; 48 hours of hospitalisation and/or death. 48 hours of hospitalisation for the following reasons: (I) arrhythmia (causing hemodynamic instability and requiring continuous monitoring and/or cardiac support, as indicated by mean arterial pressure \<65 mm Hg, and/or serum lactate \>2 mmol/L) and/or (II) Acute Respiratory Distress Syndrome (ARDS): severe hypoxaemic respiratory failure indicated by a Partial Pressure of Oxygen (PaO2)/Fraction of inspired oxygen (FiO2) \<300 mmHg according to the Berlin definition and/or (III) circulatory shock (the requirement of continuous vasopressor support to maintain mean arterial pressure \<65 mmHg and/or serum lactate \>2 mmol/L) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The number of emergency, hospital admission and intensive care admission | 12 months | The number of participants, who required the admission to each type of level of care assessed by the investigator. |
| Length of hospitalization and intensive care unit stay | 12 months | The time spent in hospital and on the intensive care unit in days collected at the end of the trial from medical records. |
| The number of general practitioner visits | 12 months | The number of participants, who required general practitioner visit assessed by the investigator. |
| Lifestyle changes | 12 months | The reached changes in lifestyle including mental and physical status will be assessed by a questionnaire. The questions related to the coronavirus epidemic in will cover in 3 fields: concerns for self, concerns for family, feeling of being overwhelmed on account of news on the epidemic. The answers can be given by a scale ranging from 1-10 points. Higher score indicates greater level of distress. One question assessess the subjective feeling of being supported, where yes indicates adequate feeling of support and no indicates feeling of being unsupported and/or lonely. |
| The cost of care | 12 months | The financial demand of the treatment of COVID-19 infection spent on each patient will be calculated by a healthcare economist after the trial is completed. |
| Organ dysfunction | 12 months | The number of cases, where the organ dysfunction (central nervous system, cardiovascular, respiratory, renal, liver, hematological) was present, measured daily during the hospital stay , assessed by the physician at the hospital/ICU. |
Countries
Hungary